BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 23382473)

  • 1. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.
    Li Z; Herold T; He C; Valk PJ; Chen P; Jurinovic V; Mansmann U; Radmacher MD; Maharry KS; Sun M; Yang X; Huang H; Jiang X; Sauerland MC; Büchner T; Hiddemann W; Elkahloun A; Neilly MB; Zhang Y; Larson RA; Le Beau MM; Caligiuri MA; Döhner K; Bullinger L; Liu PP; Delwel R; Marcucci G; Lowenberg B; Bloomfield CD; Rowley JD; Bohlander SK; Chen J
    J Clin Oncol; 2013 Mar; 31(9):1172-81. PubMed ID: 23382473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients.
    Tsai CH; Yao CY; Tien FM; Tang JL; Kuo YY; Chiu YC; Lin CC; Tseng MH; Peng YL; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
    EBioMedicine; 2019 Feb; 40():240-250. PubMed ID: 30662003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a promising 5-gene prognostic model for pediatric acute myeloid leukemia.
    Tao Y; Wei L; Shiba N; Tomizawa D; Hayashi Y; Ogawa S; Chen L; You H
    Mol Biomed; 2024 Jan; 5(1):1. PubMed ID: 38163849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
    Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia.
    Chen Z; Song J; Wang W; Bai J; Zhang Y; Shi J; Bai J; Zhou Y
    Am J Hematol; 2021 Nov; 96(11):1385-1395. PubMed ID: 34339537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia.
    Wang M; Lindberg J; Klevebring D; Nilsson C; Lehmann S; Grönberg H; Rantalainen M
    J Natl Cancer Inst; 2018 Oct; 110(10):1094-1101. PubMed ID: 29506270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a 10-gene prognostic signature for acute myeloid leukaemia.
    Yang Z; Shang J; Li N; Zhang L; Tang T; Tian G; Chen X
    J Cell Mol Med; 2020 Apr; 24(8):4510-4523. PubMed ID: 32150667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis and Characterization of Immune Microenvironment in Acute Myeloid Leukemia Through Identification of an Autophagy-Related Signature.
    Fu D; Zhang B; Wu S; Zhang Y; Xie J; Ning W; Jiang H
    Front Immunol; 2021; 12():695865. PubMed ID: 34135913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stellae-123 gene expression signature improved risk stratification in taiwanese acute myeloid leukemia patients.
    Wang YH; Orgueira AM; Lin CC; Yao CY; Lo MY; Tsai CH; de la Fuente Burguera A; Hou HA; Chou WC; Tien HF
    Sci Rep; 2024 May; 14(1):11064. PubMed ID: 38744924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying a novel 5-gene signature predicting clinical outcomes in acute myeloid leukemia.
    Sha K; Lu Y; Zhang P; Pei R; Shi X; Fan Z; Chen L
    Clin Transl Oncol; 2021 Mar; 23(3):648-656. PubMed ID: 32776271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study.
    Wagner S; Vadakekolathu J; Tasian SK; Altmann H; Bornhäuser M; Pockley AG; Ball GR; Rutella S
    Blood Adv; 2019 Apr; 3(8):1330-1346. PubMed ID: 31015209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia.
    Guo C; Gao YY; Ju QQ; Zhang CX; Gong M; Li ZL
    BMC Cancer; 2020 Sep; 20(1):841. PubMed ID: 32883226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.
    Röllig C; Bornhäuser M; Thiede C; Taube F; Kramer M; Mohr B; Aulitzky W; Bodenstein H; Tischler HJ; Stuhlmann R; Schuler U; Stölzel F; von Bonin M; Wandt H; Schäfer-Eckart K; Schaich M; Ehninger G
    J Clin Oncol; 2011 Jul; 29(20):2758-65. PubMed ID: 21632498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.
    Wang M; Lindberg J; Klevebring D; Nilsson C; Mer AS; Rantalainen M; Lehmann S; Grönberg H
    Leukemia; 2017 Oct; 31(10):2029-2036. PubMed ID: 28167833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.
    Hemmati PG; Vuong LG; Terwey TH; Jehn CF; le Coutre P; Penack O; Na IK; Dörken B; Arnold R
    Eur J Haematol; 2017 Feb; 98(2):160-168. PubMed ID: 27706846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
    Metzeler KH; Becker H; Maharry K; Radmacher MD; Kohlschmidt J; Mrózek K; Nicolet D; Whitman SP; Wu YZ; Schwind S; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    Blood; 2011 Dec; 118(26):6920-9. PubMed ID: 22031865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-gene expression-based risk score can refine the European LeukemiaNet AML classification.
    Wilop S; Chou WC; Jost E; Crysandt M; Panse J; Chuang MK; Brümmendorf TH; Wagner W; Tien HF; Kharabi Masouleh B
    J Hematol Oncol; 2016 Sep; 9(1):78. PubMed ID: 27585840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
    Metzeler KH; Hummel M; Bloomfield CD; Spiekermann K; Braess J; Sauerland MC; Heinecke A; Radmacher M; Marcucci G; Whitman SP; Maharry K; Paschka P; Larson RA; Berdel WE; Büchner T; Wörmann B; Mansmann U; Hiddemann W; Bohlander SK; Buske C; ;
    Blood; 2008 Nov; 112(10):4193-201. PubMed ID: 18716133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.